Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744755 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Phase 3 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 353
- Enrollment target
NCT02744755: Completed Phase 3 study, sponsored by Sandoz.
NCT02744755 is a Phase 3 study that has completed, run by Sandoz. The registered enrollment target is 353 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02744755, a Phase 3 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 353 participants
- Enrollment target
Study Summary
Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
Primary Outcome
Disease activity score (DAS) 28-CRP is based on 28-joint count (tender and swollen joints), C-reactive protein and patient's assessment of global disease activity (GDA) or general health (GH), values range from 0.96 to 10.0 while higher values mean a higher disease activity. • A DAS28-CRP value \>5.1 corresponds to a high disease activity • A DAS28-CRP value between 3.2 and 5.1 corresponds to a moderate disease activity • A DAS28-CRP value between 2.6 and 3.2 corresponds to a low disease activit
Interventions
- BIOLOGICAL Adalimumab - GP2017
- BIOLOGICAL Adalimumab - US licensed Humira
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2017-09-26 |
| Phase | Phase 3 |
What the finished NCT02744755 record still lists
NCT02744755 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 2 interventions - of which Adalimumab - GP2017 is the first listed.
NCT02744755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02744755 about?
NCT02744755 is a clinical study titled "Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis". Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
What is the current status of trial NCT02744755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2016-03-31. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT02744755?
The interventions under investigation include: Adalimumab - GP2017 (BIOLOGICAL), Adalimumab - US licensed Humira (BIOLOGICAL).
Who is sponsoring clinical trial NCT02744755?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02744755's enrollment target sits among peer trials
353 1028th of 2000 higher than 971 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI